Lupin to divest entire stake in Japanese subsidiary Kyowa Pharma to PE fund Unison Capital Partners for over Rs 3,702 cr

Under the terms of agreement, Lupin's subsidiary Nanomi BV will divest its entire stake in Kyowa to Unison's entity Plutus Ltd for an enterprise value of JPY 57,361

Press Trust of India November 11, 2019 19:21:18 IST
Lupin to divest entire stake in Japanese subsidiary Kyowa Pharma to PE fund Unison Capital Partners for over Rs 3,702 cr
  • The Mumbai-based company has entered into a definitive agreement for sale of its entire stake (99.82 percent) in Kyowa, Lupin said in a statement

  • Under the terms of agreement, Lupin's subsidiary Nanomi BV will divest its entire stake in Kyowa to Unison's entity Plutus Ltd for an enterprise value of JPY 57,361

  • Shares of Lupin on Monday ended 2.44 percent higher at Rs 735.95 apiece on the BSE

New Delhi: Drug major Lupin on Monday said its board has approved selling its entire stake in Japanese subsidiary Kyowa Pharmaceutical Industry to Japan-based private equity fund Unison Capital Partners for an enterprise value of JPY 57,361 million (Rs 3,702.4 crore).

The Mumbai-based company has entered into a definitive agreement for sale of its entire stake (99.82 percent) in Kyowa, Lupin said in a statement.

Lupin to divest entire stake in Japanese subsidiary Kyowa Pharma to PE fund Unison Capital Partners for over Rs 3702 cr

Representational image. Reuters

Under the terms of agreement, Lupin's subsidiary Nanomi BV will divest its entire stake in Kyowa to Unison's entity Plutus Ltd for an enterprise value of JPY 57,361, it added.

"This transaction is aligned with our vision to focus on our key markets and strategic priorities to achieve sustainable growth in the mid to long-term," Lupin CEO Vinita Gupta said.

The deal proceeds will be utilised to strengthen company's balance sheet as well as provide growth capital to support organic and inorganic initiatives for our focus markets, she added.

As per the company, the deal would help reduce its net debt to Rs 1,129 crore as compared with Rs 4,361.8 crore as on September 30, 2019.

"We believe that the partnership with Unison will enable Kyowa to leverage its strong platform and human capital to achieve its full potential. We remain committed to advancing our complex generics, biosimilars and specialty portfolio globally, including Japan," Lupin Managing Director Nilesh Gupta said.

Lupin had acquired Kyowa in 2007.

Commenting on the deal, Unison Founding Partner Tatsuya Hayashi said: "We look forward to actively working with Kyowa to leverage our unique set of resources in the healthcare market – including our own portfolio companies, and our network of experienced healthcare advisors and strategic partners – to enable Kyowa's vision of growth."

Shares of Lupin on Monday ended 2.44 percent higher at Rs 735.95 apiece on the BSE.

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Lupin reports Rs 152 cr loss in Q3 on one-time provisioning for litigation expenses; income from operations rise
Business

Lupin reports Rs 152 cr loss in Q3 on one-time provisioning for litigation expenses; income from operations rise

On 12 December, 2018, the General Court of the European Union delivered its judgment concerning Lupin's appeal against the European Commission's 2014 decision in a litigation related to Perindopril.

Lupin gets EIR from USFDA for Nagpur plant; MD says committed to enhance compliance, quality standards at all sites
Business

Lupin gets EIR from USFDA for Nagpur plant; MD says committed to enhance compliance, quality standards at all sites

Drug maker Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Nagpur

Lupin Q1 net profit dips by 16% at Rs 525.02 cr, falling overseas sales hit margins
Business

Lupin Q1 net profit dips by 16% at Rs 525.02 cr, falling overseas sales hit margins

The company had posted a net profit after taxes and minority interest of Rs 624.74 crore for the corresponding period of the previous fiscal, Lupin said in a filing to BSE.